Clinical Trials
17
Active:8
Completed:7
Trial Phases
3 Phases
Phase 1:10
Phase 2:4
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
10 (62.5%)Phase 2
4 (25.0%)Phase 3
2 (12.5%)Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Phase 2
Terminated
- Conditions
- Chronic ProstatitisChronic Pelvic Pain Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03500159
- Locations
- 🇺🇸
Site 1026, Homewood, Alabama, United States
🇺🇸Site 1010, Mobile, Alabama, United States
🇺🇸Site 1004, Tucson, Arizona, United States
Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Combined Oral Contraceptive
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03478020
- Locations
- 🇳🇱
PRA Health Sciences - Early Development Serices, Groningen, Netherlands
Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03185195
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
Phase 3
- Conditions
- Chronic Interstitial CystitisInterstitial CystitisBladder Pain SyndromePainful Bladder Syndrome
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 433
- Registration Number
- NCT02858453
- Locations
- 🇺🇸
Site 9035, Homewood, Alabama, United States
🇺🇸Site 9026, Tucson, Arizona, United States
🇺🇸Site 9064, Little Rock, Arkansas, United States
Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02324972
- Locations
- 🇨🇦
AQX-Innovaderm site, Montreal, Quebec, Canada
- Prev
- 1
- 2
- Next
News
No news found